Russia’s competition authority approved of Sistema’s buyout of Veropharm on Monday, and, as a result, shares surged in the Moscow stock exchange for two of nation’s pharmaceutical companies, Veropharm and 36.6. Shares in 36.6 rose 6.7 percent, while shares for Veroharm – Russia’s third largest drug maker – rose 9.7 percent. 36.6 had previously announced it was ready to sell its share in Veropharm, which amounted to 51.8 percent of the company, to pay off debts. Russia’s Federal Anti-Monopoly Service has approved of the merger as long as certain conditions are met, though there is no word yet on what those conditions are.
Featured News
South Korean Steelmaker POSCO Expands Supplier Support Pact With Antitrust Regulator
Jul 16, 2026 by
CPI
FCC’s Carr Criticizes California-Led Bid to Block Paramount-Warner Bros. Discovery Deal
Jul 16, 2026 by
CPI
EU Top Court Upholds Antitrust Powers to Seize Corporate Emails
Jul 16, 2026 by
CPI
Uber Launches $14.8 Billion Bid for Delivery Hero in Landmark Food Delivery Deal
Jul 16, 2026 by
CPI
EU Orders Google to Open Android and Search Data to Rival AI Services
Jul 16, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Agentic AI & Antitrust
Jul 16, 2026 by
CPI
AI Agents and Collusion: The Two Faces of Agentic AI
Jul 16, 2026 by
Giovanna Massarotto
Agentic AI’s Regulatory Conundrum
Jul 16, 2026 by
Anant Raut
Inter-AI-Agent Competition
Jul 16, 2026 by
Stefan Thomas
Navigating the Increasing Regulatory Scrutiny of AI-Pricing Tools: Competition and Other Emerging Risks
Jul 16, 2026 by
Mark Krotoski & Vinny Sidhu